drugset / Trial / NCT01688336
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.
Timeline
- Start
- 2012-01
- Primary completion
- 2016-08-22
- Completion
- 2016-11-22
Outcome
Outcome not reported
Stopped: “Results unlikely to impact treatment patterns. Time to complete not justified.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |